Lilly has unveiled promising results from a Phase III study of a lung cancer treatment which showed improved overall survival in patients. The news is a welcome relief to Lilly, which has endured a ...

Eli Lilly and Company’s LLY announced that a late-stage study evaluating its already approved cancer drug, Cyramza for the second-line treatment of liver cancer met the primary as well as secondary ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...

Adding Lilly’s biologic Cyramza (ramucirumab) to the chemotherapy paclitaxel significantly boosted median overall survival in patients with advanced gastric (stomach) cancer or gastroesophageal ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...